Cargando…
Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study)
Gut microbiota is believed to be a major determinant of health outcomes. We hypothesised that a novel oral microbiome formula (SIM01) can reduce the risk of adverse health outcomes in at-risk subjects during the coronavirus disease 2019 (COVID-19) pandemic. In this single-centre, double-blind, rando...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143994/ https://www.ncbi.nlm.nih.gov/pubmed/37111201 http://dx.doi.org/10.3390/nu15081982 |
_version_ | 1785033996458000384 |
---|---|
author | Wong, Martin C. S. Zhang, Lin Ching, Jessica Y. L. Mak, Joyce W. Y. Huang, Junjie Wang, Shilan Mok, Chris K. P. Wong, Angie Chiu, Oi-Lee Fung, Yee-Ting Cheong, Pui-Kuan Tun, Hein-Min Ng, Siew C. Chan, Francis K. L. |
author_facet | Wong, Martin C. S. Zhang, Lin Ching, Jessica Y. L. Mak, Joyce W. Y. Huang, Junjie Wang, Shilan Mok, Chris K. P. Wong, Angie Chiu, Oi-Lee Fung, Yee-Ting Cheong, Pui-Kuan Tun, Hein-Min Ng, Siew C. Chan, Francis K. L. |
author_sort | Wong, Martin C. S. |
collection | PubMed |
description | Gut microbiota is believed to be a major determinant of health outcomes. We hypothesised that a novel oral microbiome formula (SIM01) can reduce the risk of adverse health outcomes in at-risk subjects during the coronavirus disease 2019 (COVID-19) pandemic. In this single-centre, double-blind, randomised, placebo-controlled trial, we recruited subjects aged ≥65 years or with type two diabetes mellitus. Eligible subjects were randomised in a 1:1 ratio to receive three months of SIM01 or placebo (vitamin C) within one week of the first COVID-19 vaccine dose. Both the researchers and participants were blinded to the groups allocated. The rate of adverse health outcomes was significantly lower in the SIM01 group than the placebo at one month (6 [2.9%] vs. 25 [12.6], p < 0.001) and three months (0 vs. 5 [3.1%], p = 0.025). At three months, more subjects who received SIM01 than the placebo reported better sleep quality (53 [41.4%] vs. 22 [19.3%], p < 0.001), improved skin condition (18 [14.1%] vs. 8 [7.0%], p = 0.043), and better mood (27 [21.2%] vs. 13 [11.4%], p = 0.043). Subjects who received SIM01 showed a significant increase in beneficial Bifidobacteria and butyrate-producing bacteria in faecal samples and strengthened the microbial ecology network. SIM01 reduced adverse health outcomes and restored gut dysbiosis in elderly and diabetes patients during the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-10143994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101439942023-04-29 Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) Wong, Martin C. S. Zhang, Lin Ching, Jessica Y. L. Mak, Joyce W. Y. Huang, Junjie Wang, Shilan Mok, Chris K. P. Wong, Angie Chiu, Oi-Lee Fung, Yee-Ting Cheong, Pui-Kuan Tun, Hein-Min Ng, Siew C. Chan, Francis K. L. Nutrients Article Gut microbiota is believed to be a major determinant of health outcomes. We hypothesised that a novel oral microbiome formula (SIM01) can reduce the risk of adverse health outcomes in at-risk subjects during the coronavirus disease 2019 (COVID-19) pandemic. In this single-centre, double-blind, randomised, placebo-controlled trial, we recruited subjects aged ≥65 years or with type two diabetes mellitus. Eligible subjects were randomised in a 1:1 ratio to receive three months of SIM01 or placebo (vitamin C) within one week of the first COVID-19 vaccine dose. Both the researchers and participants were blinded to the groups allocated. The rate of adverse health outcomes was significantly lower in the SIM01 group than the placebo at one month (6 [2.9%] vs. 25 [12.6], p < 0.001) and three months (0 vs. 5 [3.1%], p = 0.025). At three months, more subjects who received SIM01 than the placebo reported better sleep quality (53 [41.4%] vs. 22 [19.3%], p < 0.001), improved skin condition (18 [14.1%] vs. 8 [7.0%], p = 0.043), and better mood (27 [21.2%] vs. 13 [11.4%], p = 0.043). Subjects who received SIM01 showed a significant increase in beneficial Bifidobacteria and butyrate-producing bacteria in faecal samples and strengthened the microbial ecology network. SIM01 reduced adverse health outcomes and restored gut dysbiosis in elderly and diabetes patients during the COVID-19 pandemic. MDPI 2023-04-20 /pmc/articles/PMC10143994/ /pubmed/37111201 http://dx.doi.org/10.3390/nu15081982 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wong, Martin C. S. Zhang, Lin Ching, Jessica Y. L. Mak, Joyce W. Y. Huang, Junjie Wang, Shilan Mok, Chris K. P. Wong, Angie Chiu, Oi-Lee Fung, Yee-Ting Cheong, Pui-Kuan Tun, Hein-Min Ng, Siew C. Chan, Francis K. L. Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) |
title | Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) |
title_full | Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) |
title_fullStr | Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) |
title_full_unstemmed | Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) |
title_short | Effects of Gut Microbiome Modulation on Reducing Adverse Health Outcomes among Elderly and Diabetes Patients during the COVID-19 Pandemic: A Randomised, Double-Blind, Placebo-Controlled Trial (IMPACT Study) |
title_sort | effects of gut microbiome modulation on reducing adverse health outcomes among elderly and diabetes patients during the covid-19 pandemic: a randomised, double-blind, placebo-controlled trial (impact study) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143994/ https://www.ncbi.nlm.nih.gov/pubmed/37111201 http://dx.doi.org/10.3390/nu15081982 |
work_keys_str_mv | AT wongmartincs effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT zhanglin effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT chingjessicayl effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT makjoycewy effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT huangjunjie effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT wangshilan effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT mokchriskp effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT wongangie effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT chiuoilee effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT fungyeeting effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT cheongpuikuan effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT tunheinmin effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT ngsiewc effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy AT chanfranciskl effectsofgutmicrobiomemodulationonreducingadversehealthoutcomesamongelderlyanddiabetespatientsduringthecovid19pandemicarandomiseddoubleblindplacebocontrolledtrialimpactstudy |